Kelly Donoghue receives the News 2 Cool Teacher award
Mrs. Donoghue receives our last News 2 Cool Teacher Award for this school year.
Kelly Donoghue has been a teacher at Summerville High School for twelve years, teaching Math and Engineering. She is in her ninth year as the Media Technology teacher, teaching a film and broadcasting course. Media Technology has a weekly news show that shares stories developed by students that impact or celebrate the lives of other students, complete with weekly news meetings, with Donoghue serving as the news director. Students also create a short film from start to finish.
It's a role that comes easily for Donoghue. The New Jersey native served as a Chief Photojournalist for News 2 for six years. Students and school leaders say they love Donoghue's sense of humor, her passion, and the expertise she brings to the classroom every day. Mrs. Donoghue says her students have changed her life, and she feels Blessed.
Congratulations, Mrs. Kelly Donoghue!
Even though the school year is wrapping up, you can still nominate a Cool School, Teacher, or Principal for this upcoming school year. Send an email to Octavia Mitchell at omitchell@wcbd.com.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Thunder Valley Casino Resort guest wins more than $600,000 on $7 bet
( — A guest of Thunder Valley Casino Resort took home more than half a million dollars after playing Buffalo Diamond Extreme on a penny denomination machine. Officials said the guest placed a $7 bet, earning themselves a $622,352.71 jackpot. Video Above: Can you increase your odds of winning the Powerball jackpot? 'This is what Thunder Valley is all about, extraordinary fortune, unforgettable experiences, and life-changing wins for our guests,' said Dawn Clayton, General Manager of Thunder Valley Casino Resort. 'We are thrilled to see another jackpot of this magnitude, and what makes Thunder Valley truly special is that jackpots are happening all the time, every day, across our casino. Whether it is a massive six- or seven-figure prize or a smaller win, there is always exciting energy on our floor.' The win is followed by a string of recent jackpots at the casino, including $1.15 million jackpot, a $249,470 jackpot and multiple six-figure wins. Thunder Valley officials said the casino has earned its reputation as the 'Jackpot Capital of Northern California.' Comedian Trevor Noah to take the stage at Thunder Valley Casino Resort Guests continue to take home major and minor wins across a wide variety of slot machines and table games. To learn more about Thunder Valley, visit their website. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. Solve the daily Crossword
Yahoo
4 hours ago
- Yahoo
Recursion Pharmaceuticals (RXRX) Expands AI Drug Discovery Pipeline with New Clinical Candid
We recently published . Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the best healthcare stocks. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a clinical-stage biotechnology company integrating artificial intelligence (AI), machine learning, and high-throughput biology to accelerate drug discovery, with a focus on oncology and rare diseases. Its proprietary Recursion OS platform streamlines therapeutic identification and development. In July–August 2025, the company acquired full rights to REV102, an oral ENPP1 inhibitor from Rallybio, aimed at treating hypophosphatasia (HPP), a rare genetic disorder with no approved oral disease-modifying therapies. This acquisition expands Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)'s rare disease pipeline and gives it full control over a promising preclinical program. At the same time, the business streamlined its portfolio by discontinuing or pausing several programs, narrowing its focus to six active candidates, four in oncology and two in rare diseases. Its innovative AI-driven platform and pipeline have also drawn attention from investors seeking the best healthcare stocks in biotech. The corporation continues to expand its AI-driven capabilities, most notably through a collaboration with MIT to advance the Boltz-2 AI model on its BioHive-2 platform. This initiative aims to accelerate molecular discovery and synthesis, potentially shortening the path from discovery to clinical trials. The rollout of Recursion OS 2.0 and new partnerships with biopharma and data science firms further enhance its discovery and development capabilities. Copyright: dolgachov / 123RF Stock Photo Upcoming milestones in 2025 include multiple clinical trial initiations and data readouts, such as REC-617, a CDK7 inhibitor in oncology, and REC-4881 for familial adenomatous polyposis. Following its late 2024 merger with Exscientia, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)'s oncology pipeline has broadened, with several candidates expected to advance into human studies. While we acknowledge the potential of RXRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio
Yahoo
4 hours ago
- Yahoo
OPKO Health (OPK) Advances EBV Vaccine and GLP-1 Pipeline While Streamlining Diagnostics
We recently published . OPKO Health, Inc. (NASDAQ:OPK) is one of the best healthcare stocks. OPKO Health, Inc. (NASDAQ:OPK) is a diversified healthcare company with operations in diagnostics, pharmaceuticals, and innovative therapies, anchored by BioReference Laboratories and an expanding drug development pipeline. The company is advancing programs in immunology, endocrinology, oncology, and metabolic disorders through both internal research and strategic collaborations. In 2025, OPKO Health, Inc. (NASDAQ:OPK) made notable progress across multiple fronts. In partnership with Merck, it is advancing a Phase 1 trial for an experimental Epstein-Barr virus (EBV) vaccine, which could move to Phase 2 pending trial results. Its metabolic disease pipeline includes OPK-88006, an investigational oral GLP-1/glucagon dual agonist for obesity and metabolic-associated steatohepatitis (MASH). Data presented at ENDO 2025 demonstrated strong bioavailability and efficacy, with both oral and weekly injectable formats in development. The company is also working with Entera Bio on an oral GLP-2 agonist for short bowel syndrome, with promising PK/PD data set for presentation at the 2025 ESPEN Congress. In oncology, the business's subsidiary ModeX is developing multispecific antibody therapeutics, with four clinical candidates, including lymphoma and leukemia treatments, targeting a range of solid tumors and blood cancers, and human trials expected to begin in early 2026. Photo by National Cancer Institute on Unsplash On the diagnostics front, the FDA approved a key update to OPKO's 4KScore Test, allowing use without digital rectal examination data, broadening its role in primary care for prostate cancer risk assessment. Additionally, the planned sale of certain BioReference oncology and clinical testing assets to Labcorp, expected to close in late 2025, will allow OPKO Health, Inc. (NASDAQ:OPK) to sharpen its focus on core diagnostics and pharmaceuticals while improving operational efficiency. While we acknowledge the potential of OPK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio
